Allergan, Inc.

Other

Birgitte P S Jacky

Joanne Wang

D Dianne Hodges

Hong Zhu

Fernandez-Salas Ester

Ester Fernandez-Salas

Kei Roger Aoki

Mitchell F Brin

Patton E Garay

Amy Brideau-Andersen

Shiazah Z Malik

Donald E Frail

Hui You

A polypeptide having an amino acid sequence corresponding to a binding domain of a botulinum toxin is described. The polypeptide modulates expression of genes involved in, for example, collagen production and extra cellular matrix organization, and finds use, therefore in modulating skin quality attributes such as elasticity, firmness etc. Moreover, the polypeptide inhibits lipogenesis in specialized cells and finds use, therefore, in reducing skin oiliness, which is frequently observed in skin tissue afflicted with large pores and acne. Nucleic acids encoding the polypeptide, as well as vectors, host cells, and systems comprising the nucleic acids, are further described.

Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.

Cells useful for immuno-based botulinum toxin serotype A activity assays

Cells useful for immuno-based botulinum toxin serotype a activity assays

Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.

Botulinum toxin screening assays

Cells useful for immuno-based Botulinum toxin serotype A activity assays

Growing community of inventors

Long Beach, CA, United States of America

Birgitte P S Jacky